Select First Quarter 2025 Highlights Revenue rose 29% to $6.4 millionGross margin expanded to 46.4%Operating loss narrowed to $1.0 millionBacklog…
Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing…
FDA Breakthrough Device Designation Awarded to AVIM Therapy FDA IDE Approved for Virtue SAB U.S. Pivotal Trial for Launch NEW…
đ„ Elevate your event with Sylvie di Giusto's groundbreaking Immersive Keynote Experience, where cutting-edge 3D imaging meets actionable insights on…
According to Pixalateâs April 2025 rankings, âFotMob - Soccer Live Scoresâ, âSky Sportsâ, and âLiveScoreâ were the top three Apple…
â Strategic transformation to innovative oncology completed in Q2 2025 â â Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion…
PITTSBURGH, May 12, 2025 (GLOBE NEWSWIRE) -- Matthews Memorialization, a division of Matthews International Corporation (NASDAQ GSM: MATW) (âMatthewsâ), today…
Full data from Group 1 in the Phase 2 REGEN-007 study expected in Q2 2025FDA previously confirmed in a Q4…
Received overwhelming shareholder approval with 99.9% of votes cast in favorSimplified structure benefits shareholders through strengthened shareholder alignment, enhanced governance,…
Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and…
This website uses cookies.